-
公开(公告)号：US08236352B2
公开(公告)日：2012-08-07
申请号：US10701064
申请日：2003-11-05
申请人： H. William Bosch , Niels P. Ryde , Rajeev A. Jain , Jon Swanson , Robert Hontz , John G. Devane , Kenneth Ian Cumming , Maurice Joseph Anthony Clancy , Janet Elizabeth Codd , Gary G. Liversidge
发明人： H. William Bosch , Niels P. Ryde , Rajeev A. Jain , Jon Swanson , Robert Hontz , John G. Devane , Kenneth Ian Cumming , Maurice Joseph Anthony Clancy , Janet Elizabeth Codd , Gary G. Liversidge
CPC分类号： A61K9/1623 , A61K9/0056 , A61K9/146 , A61K9/1617 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K9/2081
摘要： The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.
摘要翻译： 本发明涉及包含格列吡嗪的纳米颗粒组合物。 组合物的格列吡嗪颗粒优选具有小于约2微米的有效平均粒度。
-
2.发明授权Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors 有权丝裂原活化蛋白（MAP）激酶抑制剂的纳米颗粒组成公开(公告)号：US07998507B2
公开(公告)日：2011-08-16
申请号：US11275069
申请日：2005-12-07
申请人： H. William Bosch , Greta G. Cary , Douglas C. Hovey , Rajeev A. Jain , Laura J. Kline , Elaine Merisko-Liversidge , Kevin D. Ostrander , Niels P. Ryde , Stephen B. Ruddy
发明人： H. William Bosch , Greta G. Cary , Douglas C. Hovey , Rajeev A. Jain , Laura J. Kline , Elaine Merisko-Liversidge , Kevin D. Ostrander , Niels P. Ryde , Stephen B. Ruddy
IPC分类号： A61K9/14 , A61K9/00 , A61K31/66 , A61K31/385 , A61K31/522 , A61K31/525 , A61K31/557 , A61K36/82 , A61K36/328 , A61K36/886 , A61K38/17 , A61K48/00
CPC分类号： A61K38/1709 , A61K9/0075 , A61K9/146 , A61K9/2022 , A61K31/385 , A61K31/522 , A61K31/525 , A61K31/557 , A61K31/66
摘要： Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
摘要翻译： 描述了包含至少一种难溶性MAP激酶抑制剂和至少一种表面稳定剂的纳米颗粒组合物。 纳米颗粒组合物具有小于约2000nm的平均粒度。 本发明还描述了制备和使用这些组合物的方法。
-
3.发明授权公开(公告)号：US07763278B2
公开(公告)日：2010-07-27
申请号：US10457811
申请日：2003-06-10
CPC分类号： A61K45/06 , A23L33/10 , A23L33/105 , A61K9/145 , A61K31/045 , A61K31/56
摘要： The present invention is directed to nanoparticulate compositions comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of polycosanols and other cholesterol lowering agents are described and methods of using same are taught.
摘要翻译： 本发明涉及包含一种或多种聚果糖的纳米颗粒组合物。 组合物的聚山糖醇颗粒具有小于约2000nm的有效平均粒度。 在本发明的另一方面，描述了聚山梨醇和其它降胆固醇剂的新型组合，并教导了其使用方法。
-
4.发明申请公开(公告)号：US20100143962A1
公开(公告)日：2010-06-10
申请号：US12704426
申请日：2010-02-11
CPC分类号： A61K45/06 , A23L33/10 , A23L33/105 , A61K9/145 , A61K31/045 , A61K31/56
摘要： The invention provides a culture device comprising a plurality of culture units, wherein each unit comprises a culture chamber, an inlet port for liquid supply of the culture and an outlet port for discharging liquid from the unit, wherein the inlet port is in fluid communication with the culture chamber and the culture chamber is in fluid communication with the outlet port for allowing a liquid flow through the culture chamber. The culture device is particularly suitable for testing immune cells and immunofunction in vitro. Aspects of the invention include a culture device and associated methods for cultivating immune cells and an in vitro method of analysing the effect of a test compound on immune cells.
摘要翻译： 本发明提供了一种包括多个培养单元的培养装置，其中每个单元包括培养室，用于液体供应培养物的入口和用于从该单元排出液体的出口，其中入口端口与 培养室和培养室与出口流体连通，以允许液体流过培养室。 培养装置特别适用于体外检测免疫细胞和免疫功能。 本发明的方面包括培养装置和培养免疫细胞的相关方法以及分析试验化合物对免疫细胞的作用的体外方法。
-
5.发明授权Methods of making nanoparticulate drug compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers 有权制备包含乙烯基吡咯烷酮和乙酸乙烯酯的共聚物作为表面稳定剂的纳米颗粒药物组合物的方法公开(公告)号：US07244451B2
公开(公告)日：2007-07-17
申请号：US11213765
申请日：2005-08-30
申请人： H. William Bosch , Niels P. Ryde
发明人： H. William Bosch , Niels P. Ryde
CPC分类号： A61K9/145 , A61K9/146 , A61K9/1623
摘要： The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, methods of making and using such nanoparticulate and pharmaceutical compositions.
摘要翻译： 本发明涉及纳米颗粒组合物，其包含难溶性药物和至少一种乙烯基吡咯烷酮和乙酸乙烯酯的共聚物作为吸附在药物表面上的表面稳定剂。 本发明还包括包含本发明的纳米颗粒组合物的药物组合物，制备和使用这些纳米颗粒和药物组合物的方法。
-
6.发明授权Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers 有权包含乙烯基吡咯烷酮和乙酸乙烯酯的共聚物作为表面稳定剂的纳米微粒组合物公开(公告)号：US06969529B2
公开(公告)日：2005-11-29
申请号：US10345312
申请日：2003-01-16
申请人： H. William Bosch , Niels P. Ryde
发明人： H. William Bosch , Niels P. Ryde
CPC分类号： A61K9/145 , A61K9/146 , A61K9/1623
摘要： The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, methods of making and using such nanoparticulate and pharmaceutical compositions.
摘要翻译： 本发明涉及纳米颗粒组合物，其包含难溶性药物和至少一种乙烯基吡咯烷酮和乙酸乙烯酯的共聚物作为吸附在药物表面上的表面稳定剂。 本发明还包括包含本发明的纳米颗粒组合物的药物组合物，制备和使用这些纳米颗粒和药物组合物的方法。
-
7.发明授权公开(公告)号：US07695739B2
公开(公告)日：2010-04-13
申请号：US11650412
申请日：2007-01-08
申请人： Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
发明人： Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
CPC分类号： A61K9/1635 , A61K9/0095 , A61K9/145 , A61K9/146 , A61K9/1623
摘要： Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
摘要翻译： 公开了用于评价水溶性差的活性剂的剂型的体内再分散性的体外方法。 该方法利用代表体内人体生理条件的介质。
-
8.发明申请公开(公告)号：US20090074875A1
公开(公告)日：2009-03-19
申请号：US12292091
申请日：2008-11-12
申请人： Christian F. Wertz , Niels P. Ryde
发明人： Christian F. Wertz , Niels P. Ryde
CPC分类号： A61K47/42 , A61K8/02 , A61K8/66 , A61K9/145 , A61K9/146 , A61K31/045 , A61K31/047 , A61K31/192 , A61K31/327 , A61K31/337 , A61K31/496 , A61K31/569 , A61K31/573 , A61K31/58 , A61K33/04 , A61K45/06 , A61K47/6907 , A61K49/0438 , A61K2800/413 , A61Q19/00 , B82Y5/00 , Y10S977/702 , Y10S977/717 , Y10S977/739 , Y10S977/904 , Y10S977/914
摘要： The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.
摘要翻译： 本发明涉及包含溶菌酶作为表面稳定剂的纳米颗粒活性剂组合物。 本发明还包括包含本发明的纳米颗粒活性剂组合物的药物组合物以及制备和使用这些纳米颗粒和药物组合物的方法。
-
9.发明授权公开(公告)号：US07459283B2
公开(公告)日：2008-12-02
申请号：US10357514
申请日：2003-02-04
申请人： Christian F. Wertz , Niels P. Ryde
发明人： Christian F. Wertz , Niels P. Ryde
CPC分类号： A61K47/42 , A61K8/02 , A61K8/66 , A61K9/145 , A61K9/146 , A61K31/045 , A61K31/047 , A61K31/192 , A61K31/327 , A61K31/337 , A61K31/496 , A61K31/569 , A61K31/573 , A61K31/58 , A61K33/04 , A61K45/06 , A61K47/6907 , A61K49/0438 , A61K2800/413 , A61Q19/00 , B82Y5/00 , Y10S977/702 , Y10S977/717 , Y10S977/739 , Y10S977/904 , Y10S977/914
摘要： The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.
摘要翻译： 本发明涉及包含溶菌酶作为表面稳定剂的纳米颗粒活性剂组合物。 本发明还包括包含本发明的纳米颗粒活性剂组合物的药物组合物以及制备和使用这些纳米颗粒和药物组合物的方法。
-
10.发明授权公开(公告)号：US07198795B2
公开(公告)日：2007-04-03
申请号：US10323736
申请日：2002-12-20
申请人： Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
发明人： Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
CPC分类号： A61K9/1635 , A61K9/0095 , A61K9/145 , A61K9/146 , A61K9/1623
摘要： Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
摘要翻译： 公开了用于评价水溶性差的活性剂的剂型的体内再分散性的体外方法。 该方法利用代表体内人体生理条件的介质。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.071 秒)
